| Catalog No. | HV974226 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Functional assay, Research in vivo |
|---|
| Isotype | Fusion - [CD80 (B7-1, CD28LG1) fragment (1-107)]2 - IGHG1 Fc (Fragment constant) |
|---|
| Expression system |
Mammalian Cells |
| Target |
B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274, CD28, TP44, T-cell-specific surface glycoprotein CD28, CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
Q9NZQ7 & P10747 & P16410 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | ALPN-202, CD80vIgD-Fc, 2307144-64-3 |
|---|
| Background | Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells.
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
